Rutin impedes human low-density lipoprotein from non-enzymatic glycation: A mechanistic insight against diabetes-related disorders

Int J Biol Macromol. 2023 May 31:238:124151. doi: 10.1016/j.ijbiomac.2023.124151. Epub 2023 Mar 22.

Abstract

Glycation of human low-density protein (LDL) has an essential contribution to cardiovascular diseases. Natural compounds like rutin have been extensively studied in preventing glycation-induced oxidative stress. This study examined rutin's anti-glycation potential with glycated LDL utilizing spectroscopic and in silico methods. Glycated LDL treated with rutin, showed around 80 % inhibition in advanced glycation end-product production. Carbonyl content and lipid peroxidation like assays were used to establish the development of oxidative stress. Rutin was seen to lower the generation of oxidative stress in a dose-dependent manner. Using thioflavin-T assay and electron microscopy, rutin was suggested to restore the structural disturbances in glycated LDL. Moreover, CD spectroscopy suggested reinstation of secondary structure of glycated LDL treated with rutin. Mechanistic insights between rutin and LDL were observed through spectroscopic measures. Molecular docking study confirmed the LDL-rutin binding with a binding energy of -10.0 kcal/mol. The rutin-LDL complex was revealed to be highly stable by molecular dynamics simulation, with RMSD, RMSF, Rg, SASA, and the secondary structure of LDL remaining essentially unchanged during the simulation period. Our study suggests that rutin possesses strong anti-glycating properties, which can be useful in therapeutics, as glycated LDL has an important role in atherosclerotic cardiovascular diseases.

Keywords: Glycation; LDL; Molecular docking; Molecular dynamic simulation; Rutin.

MeSH terms

  • Cardiovascular Diseases*
  • Diabetes Mellitus*
  • Glycation End Products, Advanced
  • Humans
  • Lipoproteins, LDL / metabolism
  • Maillard Reaction
  • Molecular Docking Simulation
  • Rutin / pharmacology

Substances

  • Lipoproteins, LDL
  • Rutin
  • Glycation End Products, Advanced